Mean macular intercapillary area in eyes with diabetic macular oedema after anti-vascular endothelial growth factor therapy and its association with treatment response
- PMID: 34189816
- DOI: 10.1111/ceo.13966
Mean macular intercapillary area in eyes with diabetic macular oedema after anti-vascular endothelial growth factor therapy and its association with treatment response
Abstract
Background: To evaluate the changes in the mean macular intercapillary area (ICA) from sequential enface optical coherence tomography angiography (OCTA) images following intravitreal anti-vascular endothelial growth factor (VEGF) therapy in initially treatment-naïve eyes with diabetic macular oedema (DME).
Methods: In this multicentre retrospective study, 6 × 6 and 3 × 3 mm customised, total retinal projection enface OCTA images were collected and processed for quantitative assessment of ICA by a customised MATLAB software. Measurements were done in concentric regions centred on the fovea-with the exclusion of foveal avascular zone (FAZ)-in 0.5 mm diameter increments as well as within the intervening rings.
Results: In this study, 6 × 6 mm OCTA images from 46 eyes of 29 patients, and 3 × 3 mm OCTA images from 23 eyes of 15 patients were included. There was no significant change in mean ICA after treatment in either scan size or in any measurement regions (all p > 0.05). Multivariate analysis revealed that baseline BCVA was significantly correlated with the visual outcome (p = 0.039). Additionally, after correction for age, baseline central retinal thickness (CRT), baseline BCVA, and retinopathy severity, mean ICA in the 1.5 mm circle was found to be a significant predictor of post treatment CRT, (p = 0.006).
Conclusions: Absence of significant change in mean ICA after a minimum of three intravitreal anti-VEGF injections, may indicate that, in the short term, anti-VEGF injections neither impair nor improve macular perfusion in DME. Baseline BCVA was found to be a robust predictor of functional outcome, while inner mean ICA was a significant predictor for macular thickness outcomes.
Keywords: OCT; anti-VEGF; diabetic macular oedema; diabetic retinopathy; intravitreal.
© 2021 Royal Australian and New Zealand College of Ophthalmologists.
References
REFERENCES
-
- Ting DS, Cheung GC, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Experiment Ophthalmol. 2016;44(4):260-277.
-
- Sorour OA, Liu K, Mehta N, et al. Visual and anatomic outcomes of sustained single agent anti-VEGF treatment versus double anti-VEGF switching in the treatment of persistent diabetic macular edema. Int J Retin Vitr. 2020;6:17.
-
- Zhang L, Wang W, Gao Y, Lan J, Xie L. The efficacy and safety of current treatments in diabetic macular edema: a systematic review and network meta-analysis. PLoS One. 2016;11(7):e0159553.
-
- Baker CW, Glassman AR, Beaulieu WT, et al. Effect of initial management with Aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the Center of the Macula and Good Visual Acuity: a randomized clinical trial. JAMA. 2019;321(19):1880-1894.
-
- Reddy RK, Pieramici DJ, Gune S, et al. Efficacy of Ranibizumab in eyes with diabetic macular edema and macular nonperfusion in RIDE and RISE. Ophthalmology. 2018;125(10):1568-1574.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
